Worth Venture Partners, LLC Cassava Sciences Inc Transaction History

Worth Venture Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$2.04 - $9.64 $99,011 - $467,877	-48,535 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$3.26 - $9.65 $599,536 - $1.77 Million	-183,907 Reduced 79.12%	48,535 $200,000
Q4 2019 Feb 14, 2020	SELL	$1.1 - $6.12 $139,896 - $778,335	-127,179 Reduced 35.36%	232,442 $1.49 Million
Q3 2019 Nov 12, 2019	BUY	$1.04 - $1.45 $65,517 - $91,347	62,998 Added 21.24%	359,621 $431,000
Q2 2019 Aug 14, 2019	BUY	$1.02 - $1.34 $8,425 - $11,068	8,260 Added 2.86%	296,623 $359,000
Q1 2019 May 15, 2019	BUY	$0.92 - $1.29 $265,293 - $371,988	288,363 New	288,363 $372,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $110M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.